Tecentriq (atezolizumab)

P3, N=49, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

P1, N=339, Recruiting, Zai Lab (Shanghai) Co., Ltd. | N=112 --> 339

P3, N=60, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2026 --> Dec 2025

P3, N=670, Not yet recruiting, Boehringer Ingelheim | Trial completion date: Apr 2029 --> Jul 2029

Considering the presence of mediastinal lymph node involvement and programmed death-ligand 1 expression, the patient received four courses of cisplatin and vinorelbine, followed by treatment with atezolizumab. Programmed death-ligand 1-positive typical carcinoids are associated with a higher frequency of lymph node metastasis and poorer prognosis. Additional case investigations are required to assess the efficacy of immune checkpoint inhibitors in typical carcinoid.

Using this system, we engineered a covalent programmed death-ligand 1 (PD-L1) antagonistic nanobody with rapid crosslinking kinetics (kobs = 0.18 min-1, t1/2 = 3.8 min) and improved tumor suppression compared with envafolimab and atezolizumab. Similarly, we engineered a fast-acting covalent interleukin-18 (IL-18) (kobs = 0.54 min-1, t1/2 = 1.3 min) and a covalent miniprotein targeting the receptor binding domain (RBD) of SARS-CoV-2, demonstrating applicability across protein modalities.

P2, N=30, Active, not recruiting, University of Arizona | Trial completion date: Jan 2026 --> Jan 2027

P2, N=920, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

Chemoimmunotherapy with carboplatin, etoposide, and atezolizumab resulted in a remarkable tumor response. This is an extremely rare case of C-SCLC with rhabdomyosarcomatous differentiation that was diagnosed using a thoracoscopic biopsy and was treated with chemoimmunotherapy.

In EGFR-mutated unresectable stage III disease, durvalumab was not endorsed; osimertinib consolidation was favored. The only non-consensus item was adjuvant atezolizumab for PD-L1 ≥ 1% after platinum chemotherapy in EGFR/ALK - negative stage II - IIIA disease (AJCC 7th), lacking INVIMA approval at the time. This Delphi consensus provides a practical national framework for perioperative and unresectable stage III NSCLC management in Colombia.

P2/3, N=90, Recruiting, G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica | Not yet recruiting --> Recruiting

P1, N=200, Suspended, Amgen | Recruiting --> Suspended